Abstract
Operating in the three sectors of Pharmaceuticals, Chemicals and Plastics, Solvay is represented worldwide. This report provides a full review of the company' s activities together with sales forecasts for key products to 2010.
Operating in the three sectors of Pharmaceuticals, Chemicals and Plastics, Solvay is represented worldwide. Over 95 per cent of its sales come from outside Belgium and 49 per cent from outside the European Union.
Current Growth Drivers
Following the acquisition of Fournier Pharma, Solvay' s flagship product and principal growth driver is now fenofibrate, a treatment for lipidic disorders which is sold as Tricor in the US and Lipanthyl elsewhere. It has already achieved blockbuster status and life-cycle development should further increase sales substantially. Dualtis, a fixed-dose combination of fenofibrate and metformin was filed in the EU in July 2006 and if approved, it would be the first product on the market that combines a lipid-lowering drug with an oral antidiabetic in one tablet; Fournier is conducting Phase III trials with Zolip (fenofibrate+statin) for dyslipidaemia (launch scheduled for 2010); and a next-generation fenofibrate, HEXA/ABT335, is undergoing Phase III trials. As a result, the Cardiometabolic therapeutic area is set to become the company' s most significant in terms of sales.
Other growth drivers include: the male hormone product, Androgel, which has been Solvay' s top-selling product for a number of years; the neuroscience products, Marinol (dronabinol) and Serc (betahistine); the influenza vaccine, Influvac; the pancreatic enzyme, Creon; and Teveten (eprosartan mesylate) for hypertension.
Pipeline Analysis
Following the integration of Fournier Pharma, Solvay Pharmaceuticals is selectively reorganising its portfolio, with Cardiometabolics and Neurosciences as its new primary fields. In these areas it intends to sustain and build on its market leadership, and obtain new products through in-licensing and acquisitions.
Table of Contents
- Latest Results
- EXECUTIVE SUMMARY
- Introduction
- Financial Performance 2005
- Business Segment Performance
- Geographic Segment Performance
- Company Strategy
- Mergers, Acquisitions and Divestitures
- Key Agreements
- Discontinued Agreements
- Research and Development
- Production
- Employees
- Product Performance Forecasts
- Pipeline Analysis
- Conclusions / Outlook
- Other Factors Affecting the Bottom Line
- THERAPEUTIC AREA FOCUS
- R&D PIPELINE
- HORMONE THERAPY
- Marketed Products
- AndroGel/Andractim
- Estratest
- Prometrium
- Others
- R&D Projects
- Cetrorelix
- Growth Forecast
- CARDIOMETABOL ICS
- Marketed Products
- Physiotens/Cynt
- Teveten
- TriCor/Lipanthyl
- Others
- R&D Projects
- Daglutril
- Odiparcil
- Pulzium
- SLV319
- SLV320
- Growth Forecast
- GAS TROENTEROLO GY
- Marketed Products
- Pantoloc/Pantoloc+
- Others
- Growth Forecast
- NEUROS CIENCE
- Marketed Products
- Duodopa
- Luvox
- Marinol
- Serc/Betaserc
- Others
- R&D Projects
- Anatibant
- Bifeprunox (DU127090)
- SLV308
- SLV313/SLV314
- SLV334
- Growth Forecas
- PANCREATIC ENZYMES
- Marketed Products
- Creon
- R&D Projects
- SLV339
- Growth Forecast
- INFLUENZA VA CCINES
- Marketed Products
- Influvac
- Invivac
- R&D Projects
- Growth Forecast
- OTHERS
- Marketed Products
- R&D Projects
- Aerugen
- APPENDIX 1 - FINANCIAL PERFORMANCE
- Full Year Results 2005
- APPENDIX 2 - KEY AGREEMENTS
- 4SC
- AEterna Zentaris Inc.
- Berna Biotech AG
- Biovail Corporation
- Bristol-Myers Squibb
- Elan Corporation plc
- Eli Lilly
- Innogenetics NV
- Lundbeck
- Novozymes A/S
- Pepscan Systems BV/ServiceXS BV
- Petrovax Pharm
- QuatRx Pharmaceuticals Company
- Quintiles Transnational Corporation
- Schering-Plough
- SLA Pharma AG
- Wyeth
- APPENDIX 3 - INFRAS TRUCTURE
- Research and Development Facilities
- Manufacturing Facilities
- APPENDIX 4 - KEY PHARMACEUTICAL
- SUBSIDIARIES / JOINT VENTURES
- Subsidiaries
- Joint Ventures
- APPENDIX 5 - PRODUCT INDEX
- Index of Tables
- Principal Operating Results
- Capital Expenditure By Business Area
- Pharmaceutical R&D Expenditure By Therapeutic Area
- Sales by Business Area
- Sales By Destination
- Pharmaceutical Sales By Geographical Area
- Employees By Business Area
- Employees By Geographical Area
- Recent Product Approvals
- Major Products, Therapeutic Areas and Sales
- Major Hormone Therapy Products, 2005
- Major Cardiometabolic Products, 2005
- Major Gastroenterology Products, 2005
- Major Neuroscience Products, 2005
- Major Pancreatic Enzyme Products, 2005
- Major Influenza Vaccine Products, 2005Index of Charts
- Sales, Costs and Operating Income, 2005
- Capital Expenditure By Business Area
- Pharmaceutical R&D Expenditure By Therapeutic Area, 2005
- Sales By Business Area
- Sales By Destination, 2005
- Pharmaceutical Sales By Geographical Area, 2005
- Employees By Business Area
- Employees By Geographical Area, 2005
- Top Selling Products, 2005
- AndroGel Sales (2000A-2010E)
- Estratest Sales (2000A-2010E)
- Prometrium Sales (2000A-2010E)
- Teveten Sales (2000A-2010E)
- Luvox Sales (2000A-2010E)
- Marinol Sales (2000A-2010E)
- Serc Sales (2000A-2010E)
- Creon Sales (2000A-2010E)
- Sales, Costs and Operating Income
- Profitability and Research Ratios
- R&D Expenditure and Capital Expenditure
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
- Employees and Productivity
Index of Charts
- Sales, Costs and Operating Income, 2005
- Capital Expenditure By Business Area
- Pharmaceutical R&D Expenditure By Therapeutic Area, 2005
- Sales By Business Area
- Sales By Destination, 2005
- Pharmaceutical Sales By Geographical Area, 2005
- Employees By Business Area
- Employees By Geographical Area, 2005
- Top Selling Products, 2005
- AndroGel Sales (2000A-2010E)
- Estratest Sales (2000A-2010E)
- Prometrium Sales (2000A-2010E)
- Teveten Sales (2000A-2010E)
- Luvox Sales (2000A-2010E)
- Marinol Sales (2000A-2010E)
- Serc Sales (2000A-2010E)
- Creon Sales (2000A-2010E)
- Sales, Costs and Operating Income
- Profitability and Research Ratios
- R&D Expenditure and Capital Expenditure
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
- Employees and Productivity
